Acute Encephalopathy and Pandemic (H1N1) 2009.
Summary of "Acute Encephalopathy and Pandemic (H1N1) 2009."
To the Editor: Since the World Health Organization declared a global pandemic of influenza A pandemic (H1N1) 2009 in June 2009, the number of cases of this strain of influenza has steadily risen. Although most cases have been mild, with complete and uneventful recovery, multiple cases of severe infection with complications, including death, have been reported. Yet the neurologic complications of this virus have been rarely described. We read with interest the article by Kitcharoen et al. (1) concerning a patient with encephalopathy associated with pandemic (H1N1) 2009, which progressed to produce quadriplegia with diffuse sensory loss. In that study, however, pandemic (H1N1) 2009 virus was not isolated from the patient's cerebrospinal fluid (CSF) or brain tissue or detected by reverse transcription-PCR (RT-PCR). We report a case in an adolescent patient with encephalopathy-associated pandemic (H1N1) 2009 that was confirmed by real-time RT-PCR of CSF.
University of Ulsan College of Medicine, Seoul, South Korea.
This article was published in the following journal.
Name: Emerging infectious diseases
Medical and Biotech [MESH] Definitions
Influenza A Virus, H1n1 Subtype
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.
American Recovery And Reinvestment Act
Public Law No: 111-5, enacted February 2009, makes supplemental appropriations for job preservation and creation, infrastructure investment, energy efficiency and science, assistance to the unemployed, and State and local fiscal stabilization, for fiscal year ending September 30, 2009.
Disorders associated with acute or chronic exposure to compounds containing ARSENIC (ARSENICALS) which may be fatal. Acute oral ingestion is associated with gastrointestinal symptoms and an encephalopathy which may manifest as SEIZURES, mental status changes, and COMA. Chronic exposure is associated with mucosal irritation, desquamating rash, myalgias, peripheral neuropathy, and white transverse (Mees) lines in the fingernails. (Adams et al., Principles of Neurology, 6th ed, p1212)
SCHISTOSOMIASIS of the brain, spinal cord, or meninges caused by infections with trematodes of the genus SCHISTOSOMA (primarily SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; and SCHISTOSOMA HAEMATOBIUM in humans). S. japonicum infections of the nervous system may cause an acute meningoencephalitis or a chronic encephalopathy. S. mansoni and S. haematobium nervous system infections are associated with acute transverse myelitis involving the lower portions of the spinal cord. (From Joynt, Clinical Neurology, 1998, Ch27, pp61-2)
Encephalopathy, Bovine Spongiform
A transmissible spongiform encephalopathy of cattle associated with abnormal prion proteins in the brain. Affected animals develop excitability and salivation followed by ATAXIA. This disorder has been associated with consumption of SCRAPIE infected ruminant derived protein. This condition may be transmitted to humans, where it is referred to as variant or new variant CREUTZFELDT-JAKOB SYNDROME. (Vet Rec 1998 Jul 25;143(41):101-5)
ABSTRACT: BACKGROUND: The 2009 flu pandemic is a global outbreak of a new strain of H1N1 influenza virus. Pandemic influenza A (H1N1) 2009 has posed a serious public health challenge world-wide. Nepal...
The 2009 pandemic influenza A (H1N1) has been recognized to cause neurological complications including seizures and encephalopathy. We identified 18 children with 2009 H1N1 influenza and neurological...
Vaccination with the non-adjuvanted split-virion A/California/7/2009 influenza vaccine (pandemic H1N1 2009 vaccine) began in October 2009 in Japan. We studied how prior vaccination with a seasonal tri...
To the Editor: Tramontana et al. (1) recently described characteristics and oseltamivir resistance in hematology and oncology patients infected with pandemic (H1N1) 2009 virus. Such cases merit furthe...
Background: An influenza pandemic occurred in 2009 and myocarditis associated with the 2009 influenza A (H1N1) pandemic was reported among hospitalized patients from August 2009. Methods and Results:...
This is a prospective phase I study to evaluate the safety, tolerability and immunogenicity of nine adjuvanted candidate vaccines against pandemic influenza A (H1N1) virus.
As recommended by the Dutch Health Council, certain risk groups and health care workers in The Netherlands were vaccinated to prevent morbidity due to pandemic influenza A/H1N1. Adults wer...
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidenc...
A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANF...
In the spring of 2009, a recently emerged novel influenza A (H1N1) virus was first identified in Mexico and USA and it has continued to spread globally. The rapid global spread of a novel...